Brief: Catabasis Pharmaceuticals Announces Acquisition Of Quellis Biosciences Inc.

Astria Therapeutics

29/01/2021 13:06

Jan 29 (Reuters) - Catabasis Pharmaceuticals Inc  CATB.O :
    * CATABASIS PHARMACEUTICALS ANNOUNCES ACQUISITION OF QUELLIS
BIOSCIENCES INC.
    * CATABASIS - PLANS TO USE PRIVATE PLACEMENT FINANCING
PROCEEDS OF
$110 MILLION TO COMPLETE IND-ENABLING STUDIES, PHASE 1A, PHASE
1B/2 TRIALS OF QLS-215
    * CATABASIS - ENTERED AGREEMENT FOR SALE OF SERIES X
CONVERTIBLE
PREFERRED STOCK IN PRIVATE PLACEMENT TO GROUP OF INSTITUTIONAL
ACCREDITED INVESTORS
    * CATABASIS PHARMACEUTICALS - EXPECTS TO FILE AN
INVESTIGATIONAL
NEW DRUG APPLICATION FOR QLS-215 IN FIRST HALF OF 2022
    * CATABASIS PHARMACEUTICALS - EXPECTS TO INITIATE A PHASE
1B/2
TRIAL IN PATIENTS AFFECTED BY HAE IN 2023 WITH INITIAL RESULTS
ANTICIPATED BY END OF 2023
    * CATABASIS PHARMACEUTICALS - CATABASIS WILL CONTINUE TO BE
LED BY
ITS CURRENT MANAGEMENT TEAM
    * CATABASIS PHARMACEUTICALS - ACQUISITION OF QUELLIS WAS
STRUCTURED AS A STOCK-FOR-STOCK TRANSACTION

Source text for Eikon:  ID:nBw78PMTHa 
Further company coverage:  CATB.O 

 ((Reuters.Briefs@thomsonreuters.com;))